Introduction Natalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis (MS) treatment. Our study aimed to evaluate the effectiveness of NTZ when administered according to the extended dosing strategy compared with standard 4-weekly administration in a large Italian MS population.Materials and methods This retrospective multicentre study included patients with relapsing-remitting MS (RR-MS) who received NTZ administrations between the 1 June 2012 and the 15 May 2018 and were followed by the 'Italian MS Register'. All patients with MS were stratified into two groups based on NTZ administration schedule: standard interval dosing (SID) patients who received infusions on average from 28 to 32 days (median 30) and extended interval dosing (EID) including patients who have been infused with interval between 33 and 49 days (median 43). Clinical data were assessed at baseline (before starting NTZ), after 12 (T1) and 24 months (T2) of treatment.Results Out of 5231 patients with RR-MS screened, 2092 (mean age 43.2 +/- 12.0, 60.6% women) were enrolled. A total of 1254 (59.9%) received NTZ according to SID, and 838 (40.1%) according to EID. At 12 and 24 months, no differences in terms of annualised relapse rate and disability status were found between the two groups. Progression index and confirmed disability worsening were similar between the two groups.Discussion The use of NTZ with an extended interval schedule showed similar effectiveness compared with SID. Unchanged clinical efficacy of EID schedule may raise the question of a possible advantage in terms of tolerability and safety

Chisari, C.G., Grimaldi, L.M., Salemi, G., Ragonese, P., Iaffaldano, P., Bonavita, S., et al. (2020). Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, 91(12), 1297-1303 [10.1136/jnnp-2020-323472].

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

Salemi, Giuseppe;Ragonese, Paolo;
2020-10-21

Abstract

Introduction Natalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis (MS) treatment. Our study aimed to evaluate the effectiveness of NTZ when administered according to the extended dosing strategy compared with standard 4-weekly administration in a large Italian MS population.Materials and methods This retrospective multicentre study included patients with relapsing-remitting MS (RR-MS) who received NTZ administrations between the 1 June 2012 and the 15 May 2018 and were followed by the 'Italian MS Register'. All patients with MS were stratified into two groups based on NTZ administration schedule: standard interval dosing (SID) patients who received infusions on average from 28 to 32 days (median 30) and extended interval dosing (EID) including patients who have been infused with interval between 33 and 49 days (median 43). Clinical data were assessed at baseline (before starting NTZ), after 12 (T1) and 24 months (T2) of treatment.Results Out of 5231 patients with RR-MS screened, 2092 (mean age 43.2 +/- 12.0, 60.6% women) were enrolled. A total of 1254 (59.9%) received NTZ according to SID, and 838 (40.1%) according to EID. At 12 and 24 months, no differences in terms of annualised relapse rate and disability status were found between the two groups. Progression index and confirmed disability worsening were similar between the two groups.Discussion The use of NTZ with an extended interval schedule showed similar effectiveness compared with SID. Unchanged clinical efficacy of EID schedule may raise the question of a possible advantage in terms of tolerability and safety
21-ott-2020
Settore MED/26 - Neurologia
Chisari, C.G., Grimaldi, L.M., Salemi, G., Ragonese, P., Iaffaldano, P., Bonavita, S., et al. (2020). Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, 91(12), 1297-1303 [10.1136/jnnp-2020-323472].
File in questo prodotto:
File Dimensione Formato  
2020 Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis..pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 369.41 kB
Formato Adobe PDF
369.41 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/584688
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 27
social impact